Literature DB >> 32692928

Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension.

Kimberly A Smith1, Gregory B Waypa1, V Joseph Dudley1, G R Scott Budinger2, Hiam Abdala-Valencia2, Elizabeth Bartom3, Paul T Schumacker1,2.   

Abstract

Pulmonary hypertension (PH) and right ventricular (RV) hypertrophy frequently develop in patients with hypoxic lung disease. Chronic alveolar hypoxia (CH) promotes sustained pulmonary vasoconstriction and pulmonary artery (PA) remodeling by acting on lung cells, resulting in the development of PH. RV hypertrophy develops in response to PH, but coronary arterial hypoxemia in CH may influence that response by activating HIF-1α (hypoxia-inducible factor 1α) and/or HIF-2α in cardiomyocytes. Indeed, other studies show that the attenuation of PH in CH fails to prevent RV remodeling, suggesting that PH-independent factors regulate RV hypertrophy. Therefore, we examined the role of HIFs in RV remodeling in CH-induced PH. We deleted HIF-1α and/or HIF-2α in hearts of adult mice that were then housed under normoxia or CH (10% O2) for 4 weeks. RNA-sequencing analysis of the RV revealed that HIF-1α and HIF-2α regulate the transcription of largely distinct gene sets during CH. RV systolic pressure increased, and RV hypertrophy developed in CH. The deletion of HIF-1α in smooth muscle attenuated the CH-induced increases in RV systolic pressure but did not decrease hypertrophy. The deletion of HIF-1α in cardiomyocytes amplified RV remodeling; this was abrogated by the simultaneous loss of HIF-2α. CH decreased stroke volume and cardiac output in wild-type but not in HIF-1α-deficient hearts, suggesting that CH may cause cardiac dysfunction via HIF-dependent signaling. Collectively, these data reveal that HIF-1 and HIF-2 act together in RV cardiomyocytes to orchestrate RV remodeling in CH, with HIF-1 playing a protective role rather than driving hypertrophy.

Entities:  

Keywords:  hypoxia; hypoxia-inducible factors; right ventricular hypertrophy

Mesh:

Substances:

Year:  2020        PMID: 32692928      PMCID: PMC7605159          DOI: 10.1165/rcmb.2020-0023OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  34 in total

1.  Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein.

Authors:  D S Sohal; M Nghiem; M A Crackower; S A Witt; T R Kimball; K M Tymitz; J M Penninger; J D Molkentin
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

2.  Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.

Authors:  Norbert F Voelkel; Robert A Quaife; Leslie A Leinwand; Robyn J Barst; Michael D McGoon; Daniel R Meldrum; Jocelyn Dupuis; Carlin S Long; Lewis J Rubin; Frank W Smart; Yuichiro J Suzuki; Mark Gladwin; Elizabeth M Denholm; Dorothy B Gail
Journal:  Circulation       Date:  2006-10-24       Impact factor: 29.690

3.  Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse.

Authors:  Masakuni Kido; Lingling Du; Christopher C Sullivan; Xiaodong Li; Reena Deutsch; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

4.  Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure.

Authors:  Harm J Bogaard; Ramesh Natarajan; Scott C Henderson; Carlin S Long; Donatas Kraskauskas; Lisa Smithson; Ramzi Ockaili; Joe M McCord; Norbert F Voelkel
Journal:  Circulation       Date:  2009-11-02       Impact factor: 29.690

Review 5.  Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure.

Authors:  George W Booz; Jonathan N E Day; Kenneth M Baker
Journal:  J Mol Cell Cardiol       Date:  2002-11       Impact factor: 5.000

6.  Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Authors:  Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

7.  Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α.

Authors:  Molly K Ball; Gregory B Waypa; Paul T Mungai; Jacqueline M Nielsen; Lyubov Czech; V Joseph Dudley; Lauren Beussink; Robert W Dettman; Sara K Berkelhamer; Robin H Steinhorn; Sanjiv J Shah; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

8.  Early expression of angiogenesis factors in acute myocardial ischemia and infarction.

Authors:  S H Lee; P L Wolf; R Escudero; R Deutsch; S W Jamieson; P A Thistlethwaite
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

9.  Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α.

Authors:  Zhiyu Dai; Ming Li; John Wharton; Maggie M Zhu; You-Yang Zhao
Journal:  Circulation       Date:  2016-04-25       Impact factor: 29.690

Review 10.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.

Authors:  Brian Keith; Randall S Johnson; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

View more
  6 in total

1.  Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice.

Authors:  Benjamin D McNair; Jacob A Schlatter; Ross F Cook; Musharraf Yusifova; Danielle R Bruns
Journal:  Exp Gerontol       Date:  2021-05-07       Impact factor: 4.253

Review 2.  HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review.

Authors:  Kiichi Hirota
Journal:  Biomedicines       Date:  2021-04-24

3.  Tanreqing Injection Regulates Cell Function of Hypoxia-Induced Human Pulmonary Artery Smooth Muscle Cells (HPASMCs) through TRPC1/CX3CL1 Signaling Pathway.

Authors:  Yonghong Xiang; Fei Zheng; Qinzhe Zhang; RunJuan Zhang; Haiyan Pan; Zongdong Pang; Shimin Dai; Yurong Zhang; Ye Wu; Lunkai Yao; Mengju Su; Luying Lan
Journal:  Oxid Med Cell Longev       Date:  2022-02-11       Impact factor: 6.543

Review 4.  Mitochondrial Regulation of the Hypoxia-Inducible Factor in the Development of Pulmonary Hypertension.

Authors:  Esraa M Zeidan; Mohammad Akbar Hossain; Mahmoud El-Daly; Mohammed A S Abourehab; Mohamed M A Khalifa; Ashraf Taye
Journal:  J Clin Med       Date:  2022-09-03       Impact factor: 4.964

5.  Heart of the Matter: Divergent Roles of Hypoxia-Inducible Factors in Hypoxia-induced Right Ventricle Hypertrophy.

Authors:  Eva Nozik-Grayck; Larissa A Shimoda
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

6.  Hsa_circ_0002062 Promotes the Proliferation of Pulmonary Artery Smooth Muscle Cells by Regulating the Hsa-miR-942-5p/CDK6 Signaling Pathway.

Authors:  Yali Wang; Xiaoming Tan; Yunjiang Wu; Sipei Cao; Yueyan Lou; Liyan Zhang; Feng Hu
Journal:  Front Genet       Date:  2021-07-12       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.